Impact of first and further decompensation in patients with compensated ACLD due to MASLD

Hepatology

Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis

J Hepatol

Fortea JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, Hernández-Gea V, Aracil C, Llop E, Puente A, Roig C, Reiberger T, García-Pagan JC, Calleja JL, Ferrero-Gregori A, Mandorfer M, Villanueva C, Crespo J

doi: 10.1016/j.jhep.2024.12.017

Hepatology

β-BLOCKERS LOWER FIRST DECOMPENSATION IN PATIENTS WITH CIRRHOSIS AND ENDURING PORTAL HYPERTENSION AFTER ETIOLOGICAL TREATMENT

Clin Gastroenterol Hepatol

Turco L, Taru MG, Vitale G, Stefanescu H, Mirici Cappa F, Berardi S, Baldan A, Di Donato R, Pianta P, Vero V, Vizioli L, Procopciuc LM, Procopet B, Morelli MC, Piscaglia F

doi: 10.1016/j.cgh.2024.08.012

Hepatology

Impact of MASLD and associated comorbidities on Cognitive and Health-related Quality of Life outcomes in a Mixed MASLD-T2DM Cohort

Am J Gastroenterol

Perez-Diaz-Del-Campo N, Castelnuovo G, Ferro A, Caviglia GP, Rosso C, Dileo E, Guariglia M, Armandi A, Saba F, Saracco GM, Barutta F, Beccuti G, Gruden G, Younossi ZM, Bugianesi E

doi: 10.14309/ajg.0000000000003594

Hepatology

Prediction models for liver decompensation in compensated advanced chronic liver disease: a systematic review

Hepatology

Haghnejad V, Burke L, El Ouahabi S, Parker R, Rowe IA

doi: 10.1097/HEP.0000000000001359

Hepatology

Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

Lancet Gastroenterol Hepatol

Jachs M, Odriozola A, Turon F, Moga L, Téllez L, Fischer P, Saltini D, Kwanten WJ, Grasso M, Llop E, Mendoza YP, Armandi A, Thalhammer J, Pardo C, Colecchia A, Ravaioli F, Maasoumy B, Laleman W, Presa J, Schattenberg JM, Berzigotti A, Calleja JL, Calvaruso V, Francque S, Schepis F, Procopet B, Albillos A, Rautou PE, García-Pagán JC, Puente Á, Fortea JI, Reiberger T, Mandorfer M, SSM-100Hz/ACLD Study Group, Baveno Cooperation

doi: 10.1016/S2468-1253(24)00234-6

Hepatology

High inherited risk predicts age-associated increases in fibrosis in patients with MASLD

J Hepatol

Díaz LA, Alazawi W, Agrawal S, Arab JP, Arrese M, Idalsoaga F, Barreyro FJ, Gadano A, Marciano S, Morales JM, Villela-Nogueira C, Leite N, Couto CA, Theodoro R, Joyner de Sousa Dias Monteiro M, Oliveira CP, Pessoa MG, Alvares-da-Silva MR, Madamba E, Bettencourt R, Richards LM, Majithia AR, Khera AV, Loomba R, Ajmera V

doi: 10.1016/j.jhep.2025.04.035

Hepatology

Liver decompensation in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab: a real-life study

Clin Gastroenterol Hepatol

Stella L, Pallozzi M, Cerrito L, Santopaolo F, Tovoli F, Hollande C, Sidali S, Stefanini B, Campani C, Pellegrini E, Cabibbo G, Marra F, Piscaglia F, Gasbarrini A, Pompili M, Bouattour M, Ponziani FR

doi: 10.1016/j.cgh.2024.12.028

Hepatology

The Freiburg Index of Post-TIPS Survival (FIPS) identifies patients at risk for further decompensation and ACLF after TIPS

J Hepatol

Sturm L, Schultheiss M, Stöhr F, Labenz C, Maasoumy B, Tiede A, Praktiknjo M, Seifert LL, Auer TA, Fehrenbach U, Piecha F, Harberts A, Kluwe J, Bruns T, Pollmanns MR, Chang J, Grobelski J, Jansen C, Meyer C, Reincke M, Rohrer C, Philipp Arbabi SR, Kimmann M, Ripoll C, Zipprich A, Hinrichs J, Koehler M, Trebicka J, Kloeckner R, Thimme R, Bettinger D, German Cirrhosis Study Group of the DGVS

doi: 10.1016/j.jhep.2025.01.030

Hepatology

Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis

Gut

Trebicka J, Aguilar F, Queiroz Farias A, Lozano JJ, Sánchez-Garrido C, Usón-Raposo E, de la Peña-Ramirez C, Sidorova J, Curto-Vilalta A, Sierra-Casas P, Momoyo Zitelli P, Papp M, Pereira G, Caraceni P, Goncalves LL, Alessandria C, Torre A, Laleman W, Gadano A, Piano S, Mattos AZ, Gu W, Brol MJ, Schierwagen R, Uschner FE, Fischer J, Mendes LSC, Vargas V, Alvares-da-Silva MR, Mookerjee R, Bittencourt PL, Benitez C, Albillos A, Couto C, Mendizabal M, Bañares R, Toledo CL, Mazo DF, Janicko M, Castillo-Barradas M, Padilla Machaca PM, Gatti P, Miranda AZ, Malé-Velázquez R, Zipprich A, Castro-Lyra A, Gustot T, Bernal W, Gerbes AL, Jalan R, Fernández J, Angeli P, Carrilho FJ, Claria J, Moreau R, Arroyo V, PREDICT study and ACLARA study

doi: 10.1136/gutjnl-2024-333876

Related content

Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis

β-BLOCKERS LOWER FIRST DECOMPENSATION IN PATIENTS WITH CIRRHOSIS AND ENDURING PORTAL HYPERTENSION AFTER ETIOLOGICAL TREATMENT

Impact of MASLD and associated comorbidities on Cognitive and Health-related Quality of Life outcomes in a Mixed MASLD-T2DM Cohort

Prediction models for liver decompensation in compensated advanced chronic liver disease: a systematic review

Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

High inherited risk predicts age-associated increases in fibrosis in patients with MASLD

Liver decompensation in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab: a real-life study

The Freiburg Index of Post-TIPS Survival (FIPS) identifies patients at risk for further decompensation and ACLF after TIPS

Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis